Diagnostic performance of the Cobas MTB and Logix Smart MTB for diagnosing pulmonary and extrapulmonary tuberculosis: a cross-sectional study of diagnostic tests
Authors:
- Miguel Hueda-ZavaletaMiguel Hueda-Zavaleta
- Juan Carlos Gomez de la TorreJTJuan Carlos Gomez de la Torre
- Diana Minchón-VizcondeDMDiana Minchón-Vizconde
- Claudia Barletta-CarrilloCBClaudia Barletta-Carrillo
- Cesar Copaja-CorzoCesar Copaja-Corzo
- Gustavo Tapia-SequeirosGTGustavo Tapia-Sequeiros
- Cinthya FloresCFCinthya Flores
- Cristian PiscocheCPCristian Piscoche
- Cecilia MirandaCMCecilia Miranda
- Ada MendozaAMAda Mendoza
- Vicente A. Benites-ZapataVBVicente A. Benites-Zapata
Open Access
- 1 January 2024
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Infectious Disease
- Vol. 11
Abstract
Background: Molecular tests have contributed to reducing the mortality rate through early and accurate diagnosis of tuberculosis (TB). This is due to their low processing complexity and diagnostic accuracy superior to conventional methods. Objective: To evaluate the diagnostic performance of Cobas MTB and Logix Smart MTB compared to Xpert MTB/RIF Ultra for pulmonary tuberculosis (PTB) and extrapulmonary tuberculosis (EPTB). Design: A cross-sectional study of diagnostic tests was carried out in a clinical laboratory in Lima, Peru. Methods: All pulmonary and extrapulmonary samples from patients with presumptive TB who had been subjected to smear microscopy, Xpert MTB/RIF Ultra, Cobas MTB, Logix Smart MTB, and mycobacteria culture were included to determine their diagnostic performance. Results: A total of 175 samples were included, 102 (58.3%) of pulmonary origin and 73 (41.7%) of extrapulmonary origin. Among the total samples, 19 (10.9%) had positive cultures (all were pulmonary samples), 48 (27.4%) had positive Xpert MTB/RIF Ultra results, 45 (25.7%) had positive Cobas MTB results, and 36 (20.6%) had positive Logix Smart MTB results. The agreement between Cobas MTB and Logix Smart with the Xpert MTB/RIF Ultra was 97.1% and 93.8%, respectively. Compared to Xpert MTB/RIF Ultra, the area under the curve/receiver operating characteristic and sensitivity of the Cobas MTB and Logix Smart methods were 0.95 and 91.7%, and 0.90 and 81.0%, respectively. Conclusion: Cobas MTB and Logix Smart presented adequate performance for diagnosing pulmonary and extrapulmonary tuberculosis comparable to the Xpert MTB/RIF Ultra.Keywords
Funding Information
- Universidad Privada de Tacna (323-2022-UPT-CU)
This publication has 19 references indexed in Scilit:
- Feasibility, Ease-of-Use, and Operational Characteristics of World Health Organization–Recommended Moderate-Complexity Automated Nucleic Acid Amplification Tests for the Detection of Tuberculosis and Resistance to Rifampicin and IsoniazidThe Journal of Molecular Diagnostics, 2022
- Rapid Molecular Diagnosis of Extra-Pulmonary Tuberculosis by Xpert/RIF UltraFrontiers in Microbiology, 2022
- Clinical evaluation of the cobas® MTB-RIF/INH reagent and the cobas® 6800 for the detection of isoniazid and rifampicin resistanceTuberculosis, 2022
- Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in a clinical practice setting of ChinaDiagnostic Microbiology and Infectious Disease, 2021
- Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy studyThe Lancet Infectious Diseases, 2020
- Diagnostic accuracy of the new Xpert MTB/RIF Ultra for tuberculosis disease: A preliminary systematic review and meta-analysisInternational Journal of Infectious Diseases, 2020
- Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: A prospective cohort studyJournal of Infection, 2019
- The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB eraThe Lancet Respiratory Medicine, 2018
- Sensitivity and specificity of Cobas TaqMan MTB real-time polymerase chain reaction for culture-proven Mycobacterium tuberculosis: meta-analysis of 26999 specimens from 17 StudiesScientific Reports, 2015
- Treatment of Tuberculosis: Guidelines2010